Get the RNN Research Report and
Also Receive Our Top Trades for 2016!

Rexahn Pharmaceuticals, Inc.

“In 2016, we made significant progress across our portfolio of drug candidates, setting up a potentially transformative year for the Company in 2017,” said Peter D. Suzdak, Ph.D., Chief Executive Officer of Rexahn. “We achieved a major clinical milestone with RX-3117, with the successful completion of the first stage and the initiation of the second stage of the Phase IIa study in pancreatic cancer and we look forward to the final readout of that study in the second half of this year.” Rexahn’s … (See Research Report)
Download Research Report
on RNN Now